Cite
HARVARD Citation
Padidela, R. et al. (2020). Clinical guidelines for burosumab in the treatment of XLH in children and adolescents: British paediatric and adolescent bone group recommendations. Endocrine connections. 9 (10), pp. 1051-1056. [Online].